期刊文献+

利格列汀凝胶的大鼠体内药动学研究

Study on pharmacokinetic of linagliptin gelin rats in vivo
下载PDF
导出
摘要 凝胶剂具有缓释可控、易于涂展和吸收速度快等优点,通过研究利格列汀凝胶剂和口服给药在大鼠体内药动学差异,评估利格利汀凝胶剂的药动学相关特性.雄性SD大鼠随机分为两组,给予利格利汀凝胶(10 mg/kg,以利格利汀计)和利格利汀原药,分别在服药后按时间眼眶取血0.5 mL,利用高效液相色谱法测定不同时间点血浆中利格列汀含量,通过PK solver 2.0软件进行药动学数据分析,口服给药组血浆中主要药动学参数Cmax为983.212±32.263 ng/mL,Tmax为1.5 h,AUC(0-t)为5731.935±265.959 ng/mL*h,MRT为30.415±5.310 h,t1/2为29.077±4.847 h;凝胶给药组的药动学参数Cmax为863.011±66.053 ng/mL,Tmax为1.5 h,AUC(0-t)为4362.826±142.086 ng/mL*h,MRT为31.370±4.282 h,t1/2为31.231±4.197 h.发现利格利汀凝胶对比口服给药体内滞留时间和半衰期均延长,生物利用度差异不明显,是一种可替代利格列汀口服的良好新制剂,可进一步临床开发提升患者的依从性. Gel has some advantages of excellent control release,being easy to spread and absorbing rapidly.In the present study,we compared the pharmacokinetics of linagliptin in rats after transdermal administration by gel through the skin and oral administration,to evaluate the pharmacokinetic properties of the linagliptin gel.Male SD rats were randomly divided into 2 groups,one group was given linagliptin gel(10 mg/kg based on linagliptin)and another group was oral administrated linagliptin at a dose of 10 mg/kg.0.5 mL fundus venous plexus blood of each group was taken as samples according to the time points after administration.The plasma concentrations of linagliptin were measured by HPLC at different time points.The data of two groups were analyzed by the PK solver 2.0 system,which presented the main pharmacokinetic parameters for oral administration in the plasma as follows:Cmax=983.212±32.263 ng/mL,Tmax=1.5 h,AUC(0-t)=5731.935±265.959 ng/mL*h,MRT=30.415±5.310 h,t1/2=29.077±4.847 h;the main pharmacokinetic parameters for linagliptin gel group in the plasma:Cmax=863.011±66.053 ng/mL,Tmax=1.5 h,AUC(0-t)=4362.826±142.086 ng/mL*h,MRT=31.370±4.282 h,t1/2=31.231±4.197 h.These results showed that the retention time and half-life of Ligliptin gel were prolonged compared with oral administration,with no obvious difference in bioavailability.The linagliptin gel had potential applications to replace the linagliptin tablet.The formulation of the linagliptin gel could be further developed to improve the patients’compliance.
作者 肖学成 邢天嫣 曹国胜 卢山 向兰 XIAO Xue-cheng;XING Tian-yan;CAO Guo-sheng;LU Shan;XIANG Lan(School of Pharmacy,Hubei University of Chinese Medicine,Wuhan 430065,China;College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China)
出处 《西南民族大学学报(自然科学版)》 CAS 2021年第2期166-173,共8页 Journal of Southwest Minzu University(Natural Science Edition)
基金 湖北省教育厅科学技术研究项目(Q20192009)。
关键词 利格列汀 凝胶 药代动力学 linagliptin gel pharmacokinetics
  • 相关文献

参考文献6

二级参考文献51

  • 1张相彩,徐颖颖.高效液相色谱法同时测定苯巴比妥、苯妥英、卡马西平、茶碱的血药浓度[J].中国医院药学杂志,2005,25(11):1096-1097. 被引量:14
  • 2窦祖林,万桂芳,王小红,丘卫红,林嘉旋,林捷新,潘伟平.导尿管球囊扩张治疗环咽肌失弛缓症2例报告[J].中华物理医学与康复杂志,2006,28(3):166-170. 被引量:109
  • 3孙宝清,莫红樱,邱志辉,陈顺存,钟南山.高效液相色谱法和荧光偏振免疫法测定茶碱血药浓度方法的比较[J].广州医药,1997,28(1):10-11. 被引量:7
  • 4Grafe Mody U,Rose P,Retlich S,et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment [J]. Br J Clin Pharmacol, 2012,74 ( 1 ) : 75-85.
  • 5Owens DR,Swallow R,Dugi KA,et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulpbonylurea:a 24 week randomized study[J]. Diabet Med,2011,28(11): 1352-1361.
  • 6Scheen AJ. Pharmacokinetics of dipetidyl peptidase-4 inhibitors [J]. Diabetes Obes Metab,2010,12(8) :548-658.
  • 7Del Prato S,Barmett AH,Huisman H,et al. Effect of linagliptin monotherapy on glycaemic control and markers of 13-cell funcion inpatients with inadequately controlled type 2 diabetes:a randomized controllled trial [J]. Diabetes Obes Metab,2011,13 (3) :258-267.
  • 8Thrasher J,Daniels K,Patel S,et al. Efficacy and safety of linagliptin in black/african American patients with type 2 diabetes:a 6 month,randomized,double blind,placebo con- trolled study[J]. Endoer Pract,2013,10(5):1-33.
  • 9Kawamori R, Inagaki N,Araki E,et a 1. Linagliptin monotberapy provides superior glyeaemie control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized,placebo and active comparator --controlled, double blind study [J]. Diabetes Obes Metab, 2012,14(3 ) : 348-357.
  • 10Rosenstock J,Baron MA,Dejager S,et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes:a 24-week,double-blind,randomized trial [J]. Diabetes care, 2007,30 (2) : 217-223.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部